Understanding and identifying the unmet need of aggressive B-cell lymphomas is critical for positioning new therapies Aggressive B-cell lymphomas are a subset of non-Hodgkin’s lymphoma (NHL) that encompass a number of neoplasms that include both precursor lymphoid...
Medlior Health Outcomes Research was engaged by Celgene Canada (now a subsidiary of Bristol-Myers Squibb Company) to examine the treatment landscape for patients with multiple myeloma (MM) and the effects of lenalidomide (REVLMID®) as an immunomodulatory imide drug for both newly-diagnosed MM patients and relapsed/refractory MM patients.
Lipid-lowering Therapy Patterns and Low-density Lipoprotein-Cholesterol Management Among Patients with Acute Myocardial Infarction in Alberta, Canada
Medlior’s presentation focuses on a real-world evidence study sponsored by Amgen Inc. examining the management of patients with an acute myocardial infarction (AMI) in Alberta, Canada. AMI is a leader in disease burden and death worldwide. In order to combat AMI, modifiable factors that lower cholesterol, specifically low-density lipoprotein-cholesterol (LDL-C) are needed. Therapies designed to lower LDL-C, such as statins, also called lipid lowering therapies (LLT), are therefore important to understand the patterns of use and to what extent LDL-C is lowered. Medlior’s study utilized health system data to explore the patterns of LLT and the management of LDL-C levels in patients who experienced AMI.
Canadian real-world evidence on epidemiology, outcomes and economics of moderate-to-severe osteoarthritis
A systematic literature review Osteoarthritis (OA) is a chronic joint disease that leads to a loss of articular cartilage, resulting in painful bone-on-bone contact. Females have a higher risk of developing OA compared to males, and obese individuals are three times...
As the COVID-19 virus spreads, world governments implement control strategies This article is about an emerging and rapidly evolving public health crisis. Case and death counts change daily. If you’re interested in learning the very latest information please consult...
Medlior is looking forward to a year of innovation in health outcomes research with Real World Evidence leading the way. See our predictions for 2020.
2019 has proven to be a great year for Medlior, the healthcare industry and Real World Evidence. Read our wrap on the last year here.
Using Integrated Real-World Data in Alberta to Develop Personalized Follow-up Care Pathways for Cancer Survivors
This study will provide an integrated data source to inform follow-up clinical care pathways for cancer survivors in Alberta The odds of long-term recovery from cancer have never been better. In the 1940s only 25% of Canadians survived a cancer diagnosis, compared...
Real World Data could be used to create a better understanding of the burden of diseases such as inflammatory bowel disease and improve health outcomes
Studies on the costs of Huntington’s Disease are lacking in Canada. A real-world evidence study will be vital to future economic analyses.